fbpx

RAMP-301 | NCT06072781

The RAMP-301 trial will assess the safety and efficacy of the combination of Avutometinib plus Defactinib versus Investigator’s Choice of Treatment options (ICT) in patients with recurrent Low-grade Serous Ovarian Cancer (LGSOC) who have progressed on a prior platinum-based [...]

RAMP-301 | NCT060727812024-07-19T11:32:01+10:00

PARAGON-II | ACTRN12621000639820

PARAGON-II is a trial investigating whether a combination of two drugs (letrozole with alpelisib or letrozole with ribociclib) is an active treatment for a range of advanced gynaecological cancers that expresses hormone receptors.

PARAGON-II | ACTRN126210006398202024-07-09T17:00:40+10:00

ADELE | ACTRN12621000273886

ADELE is a randomised phase 2 trial testing the effect of ADjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk EndometriaL cancer.  

ADELE | ACTRN126210002738862024-07-09T17:00:50+10:00

IGNITE | ACTRN12619001185156P

IGNITE is testing how effective adavosertib treatment is for patients with relapsed high grade serous or endometrioid ovarian cancer with particular genetic faults, which alter how tumour cells respond to treatment.

IGNITE | ACTRN12619001185156P2024-07-09T17:01:43+10:00
Go to Top